Dayvigo Cost in Oklahoma 2026: Prices, Insurance, Medicaid and Compounding Options

What Is Lemborexant and Why Does Its Price Matter in Oklahoma?

Lemborexant, sold as Dayvigo, is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia characterized by difficulty with sleep onset or maintenance. Orexin signaling actively promotes wakefulness, and blocking both OX1R and OX2R receptors shifts the brain toward sleep without broadly suppressing the central nervous system the way older benzodiazepines do. That pharmacological difference matters clinically, but it also means Dayvigo sits in a specialty-tier pricing category that can catch Oklahoma patients off guard.

Oklahoma ranks among the states with higher rates of reported sleep difficulty. The CDC's Behavioral Risk Factor Surveillance System found that 35.2% of U.S. adults report sleeping fewer than 7 hours per night, and Oklahoma's rate has historically exceeded the national average. For patients who genuinely need a DORA rather than an over-the-counter option, cost is often the deciding factor in whether they fill the prescription.

Dayvigo is Schedule IV under the Controlled Substances Act. Oklahoma follows federal scheduling, so prescribers must comply with DEA rules governing Schedule IV dispensing, including limits on refills and electronic prescribing requirements in certain settings.

The FDA-approved prescribing information for Dayvigo specifies 5 mg once nightly as the starting dose, with an option to increase to 10 mg based on tolerability and clinical response. Neither dose is available over the counter, and no authorized generic existed as of mid-2025.

Oklahoma Retail Cash Prices for Dayvigo in 2026

The average cash-pay price at Oklahoma retail pharmacies in 2026 is roughly $85 per month for a 30-tablet supply. That figure is well below the Eisai wholesale acquisition cost (WAC) of approximately $320 per month, because pharmacy benefit managers negotiate different acquisition costs, and discount programs like GoodRx apply additional reductions at the point of sale.

Prices vary by pharmacy chain and zip code within Oklahoma. GoodRx data for lemborexant show that independent pharmacies in smaller Oklahoma cities sometimes beat the prices available at large chains, particularly when the independent pharmacy participates in a 340B-adjacent network or has negotiated its own purchasing contracts. Patients should always compare prices using GoodRx, RxSaver, or NeedyMeds before filling.

The 10 mg dose typically runs only a few dollars more per month than the 5 mg dose in cash-pay scenarios, because both tablets are manufactured at similar cost. Pharmacokinetic data from the FDA label confirm that the 10 mg dose produces roughly dose-proportional plasma exposure, so patients should not split 10 mg tablets to save money without explicit prescriber guidance, as tablet integrity affects absorption timing.

A 90-day supply filled at a mail-order pharmacy can sometimes reduce the per-tablet cost by 10 to 15 percent relative to monthly 30-day fills. Oklahoma residents with commercial insurance should verify whether their plan's mail-order benefit applies to Schedule IV medications, since some plans exclude controlled substances from mail-order dispensing.

Does Oklahoma Medicaid Cover Dayvigo?

Oklahoma Medicaid (SoonerCare) does not cover Dayvigo as of 2026. The Oklahoma Health Care Authority's preferred drug list does not include lemborexant, and there is no published prior-authorization pathway that would routinely result in coverage for this agent.

The Oklahoma Health Care Authority maintains a formulary that favors older generic sedative-hypnotics for insomnia, including zolpidem (immediate and extended release), eszopiclone, and temazepam. A SoonerCare member who cannot tolerate those agents may file a formulary exception, but approval rates for non-formulary DORAs on state Medicaid programs have been low nationally. The American Academy of Sleep Medicine's 2017 clinical practice guideline for chronic insomnia, published in the Journal of Clinical Sleep Medicine, recommends several pharmacological agents but does not confer special formulary priority to any single DORA.

Patients covered by SoonerCare have two realistic options: pay cash at the $85 monthly price point (and apply whatever manufacturer or third-party discount programs are available) or ask their prescriber about a formulary exception supported by documentation of failed trials with covered alternatives. The exception process requires a written request, clinical notes showing prior drug failures, and sometimes a peer-to-peer review call between the prescriber and the Medicaid medical director.

Dual-eligible patients (Medicare and Medicaid) face a different path. Medicare Part D covers Dayvigo on some formularies, though tier placement and cost-sharing vary by plan. Medicare's formulary search tool can identify which Oklahoma Part D plans cover lemborexant in 2026 and at what tier.

Which Oklahoma Commercial Insurance Plans Cover Dayvigo?

Most large commercial insurers operating in Oklahoma cover Dayvigo, but typically on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which can mean $80 to $180 in monthly cost-sharing depending on the plan's specific structure.

UnitedHealthcare, BlueCross BlueShield of Oklahoma, Aetna, and Cigna all list lemborexant on at least some of their Oklahoma formularies, though the tier varies by product line. Employer-sponsored plans administered by the same carriers may have different formulary rules than marketplace plans. The safest approach is to call the member services number on the insurance card and ask: "Is lemborexant (NDC 62856-0205-30 for the 5 mg, or 62856-0206-30 for the 10 mg) covered on my current plan, and what is my expected copay or coinsurance?"

Prior authorization is common. Typical criteria include a diagnosis of chronic insomnia disorder confirmed by a licensed provider, a documented trial of at least one formulary alternative (usually zolpidem or eszopiclone), and age 18 or older. Some plans additionally require that the prescriber document failure of cognitive behavioral therapy for insomnia (CBT-I) first, consistent with the AASM's recommendation that CBT-I be offered as first-line treatment. The AASM's clinical practice guideline gives CBT-I the strongest recommendation grade, with pharmacotherapy reserved for patients who cannot access or do not respond to behavioral treatment.

Once prior authorization is approved, Eisai's savings card can stack on top of commercial coverage for eligible patients, reducing the copay to as low as $0 per month (subject to monthly and annual caps; see the next section).

How the Eisai Dayvigo Savings Card Works in Oklahoma

Eisai offers a co-pay savings program for commercially insured patients that can reduce out-of-pocket costs to $0 per month, with a maximum annual benefit that the company updates periodically. The savings card is not valid for patients enrolled in any federal health care program, including Medicare, Medicaid, TRICARE, or the VA.

Enrollment is available at Eisai's official patient support site or through the prescriber's office. Oklahoma patients who are commercially insured and meet the income and eligibility criteria can activate the card before their first fill and present it at any participating Oklahoma retail pharmacy alongside their insurance card. The card functions as a secondary payer: the insurance processes first, and the savings card covers the remaining patient cost-share up to the program cap.

For cash-pay patients without any insurance coverage, Eisai also offers a separate patient assistance program for uninsured or underinsured individuals who meet income thresholds. The NeedyMeds database lists current eligibility criteria and application links for Eisai's Patient Assistance Program, which can bring the monthly cost to near zero for qualifying individuals.

Cash-pay patients who do not qualify for the patient assistance program should use a GoodRx Gold or similar discount card, which typically brings the 30-day price at major Oklahoma pharmacy chains to the $75 to $90 range. The savings card and GoodRx coupons cannot be combined at most pharmacies, so patients should compare both options at their specific pharmacy before choosing.

Is Compounded Lemborexant Legal in Oklahoma?

Compounded lemborexant is legal in Oklahoma when prepared by a licensed 503A compounding pharmacy, subject to specific conditions. Oklahoma follows federal law on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding by a licensed pharmacist operating under a valid prescription, as long as the drug is not a copy of a commercially available product made for reasons of convenience.

The FDA has not placed lemborexant on the Demonstrably Difficult to Compound list, and it is not currently on the FDA's list of drugs that may not be compounded. This means that 503A pharmacies in Oklahoma may legally compound lemborexant for individual patients under a prescription from a licensed Oklahoma prescriber, provided the pharmacy is in good standing with the Oklahoma State Board of Pharmacy.

However, the compounded product is not FDA-approved for safety, efficacy, or manufacturing quality. Patients and prescribers should verify that the compounding pharmacy has passed recent PCAB (Pharmacy Compounding Accreditation Board) inspection or equivalent state inspection. The Oklahoma State Board of Pharmacy maintains a public license lookup at Oklahoma.gov where patients can confirm a pharmacy's active status.

Compounded lemborexant may cost less than the brand product, and some Oklahoma telehealth and specialty practices have begun pairing telehealth consultations with referrals to 503A compounders for this reason. The clinical concern is bioequivalence: compounded lemborexant has not been tested in the same pharmacokinetic studies that generated the SUNRISE-1 trial's efficacy data, so the expected dose-response relationship may differ.

SUNRISE-1 and SUNRISE-2: What the Clinical Evidence Shows

SUNRISE-1 was a Phase 3, double-blind, randomized, placebo-controlled trial (N=291) published in JAMA Network Open in 2019. Patients received lemborexant 5 mg, lemborexant 10 mg, or placebo nightly for 30 days. The primary endpoints were sleep onset and sleep maintenance measured by polysomnography. Both doses significantly outperformed placebo: the 10 mg dose reduced sleep onset latency by 14.9 minutes versus placebo (P<0.001), and wake after sleep onset was reduced by 28.8 minutes versus placebo (P<0.001).

SUNRISE-2 extended the assessment to 12 months (N=949) and compared lemborexant to both placebo and zolpidem tartrate extended release 6.25 mg. Published results confirmed that lemborexant 10 mg was superior to zolpidem ER on sleep maintenance endpoints at months 1, 6, and 12, with a favorable next-morning residual sedation profile. The SUNRISE-2 data were central to the FDA's 2019 approval decision.

The most common adverse effects in both trials were somnolence (reported in 10 to 22% of patients depending on dose) and headache. Serious adverse events, including complex sleep behaviors (sleepwalking, sleep-driving), occurred rarely but prompted an FDA Boxed Warning that applies to all approved sedative-hypnotics. The FDA's Drug Safety Communication details this warning and was updated after post-marketing reports.

Next-morning driving impairment is a specific concern at the 10 mg dose. The FDA prescribing label recommends that patients not drive or operate heavy machinery the day after taking 10 mg. Oklahoma prescribers working with commercial drivers or patients with safety-sensitive occupations should factor this into dose selection.

How Oklahoma Telehealth Prescribing of Dayvigo Works

Oklahoma law permits telehealth prescribing of controlled substances, including Schedule IV medications like Dayvigo, when the prescriber meets specific requirements. After the COVID-19 public health emergency telehealth flexibilities, the DEA finalized rules that allow ongoing prescribing of Schedule III to V controlled substances via telemedicine for patients who have had at least one prior in-person visit with any DEA-registered practitioner for the condition being treated. The DEA's telemedicine regulations govern this process at the federal level, and Oklahoma has not imposed stricter requirements.

A practical consequence: an Oklahoma patient who has seen any sleep specialist or primary care physician in person for insomnia can continue receiving Dayvigo prescriptions via a telehealth platform without needing to return to an office for each renewal. First-time prescriptions for patients with no prior in-person evaluation for insomnia require an in-person visit or registration with a DEA-compliant telehealth special registration program.

Telehealth platforms serving Oklahoma patients range from large national services to Oklahoma-based practices offering video visits. Patients should verify that the platform employs a DEA-registered, Oklahoma-licensed prescriber before enrolling. The Oklahoma State Board of Medical Licensure and Supervision maintains a public license lookup for physicians.

Choosing the Right Dose: 5 mg vs. 10 mg in Cost Context

Dayvigo comes in 5 mg and 10 mg tablets. The 5 mg dose is the recommended starting point for most adults, with the 10 mg dose reserved for patients who do not achieve adequate benefit. Older adults (65 and over) and patients taking moderate CYP3A inhibitors should not exceed 5 mg per the FDA prescribing label.

From a cost standpoint, the two doses are priced similarly in the cash-pay market. Choosing 10 mg over 5 mg is therefore a clinical decision, not a financial one. Patients sometimes ask whether they can take half a 10 mg tablet to approximate a 5 mg dose and reduce cost; the prescribing information does not list tablet-splitting as a validated method, and the tablet is film-coated, so splitting may affect release characteristics.

A reasonable clinical workflow at Oklahoma telehealth and primary care practices is to start at 5 mg for 2 to 4 weeks, assess response, and titrate to 10 mg if sleep maintenance remains inadequate. The SUNRISE-1 polysomnography data showed that 10 mg produced larger reductions in wake after sleep onset than 5 mg, supporting this stepped approach.

Comparing Dayvigo to Other Sleep Medications on Cost in Oklahoma

Oklahoma patients may benefit from understanding where Dayvigo sits among alternatives. Suvorexant (Belsomra), the first approved DORA, has a similar list price but a different formulary tier on many Oklahoma plans. Generic zolpidem immediate release costs under $10 per month at most Oklahoma pharmacies and is covered by SoonerCare. Eszopiclone (generic Lunesta) runs $15 to $35 per month cash-pay.

Trazodone, used off-label for insomnia at 25 to 100 mg, is not a controlled substance and costs under $10 per month, which makes it attractive for patients with both insomnia and depression. Doxepin 3 mg and 6 mg (Silenor) is FDA-approved for sleep maintenance insomnia and costs $60 to $120 per month cash-pay in Oklahoma.

The AASM's 2017 guideline notes that clinical evidence for individual agents differs in quality and that patient-specific factors, including comorbidities and medication interactions, should drive selection. Dayvigo's differentiation over older agents is its selectivity for orexin receptors and its lack of GABA-A activity, which may translate to less dependence potential, though head-to-head long-term dependence data in real-world Oklahoma populations are limited.

Step-by-Step Guide to Getting the Lowest Dayvigo Price in Oklahoma

Getting the lowest price takes a specific sequence of actions. First, confirm your diagnosis with a licensed Oklahoma provider (in-person or via telehealth meeting DEA requirements). Second, ask whether 5 mg is clinically appropriate as a starting dose, since both dose strengths carry similar cash prices. Third, check your insurance formulary before the prescription is sent to the pharmacy: call member services or use the insurer's online drug lookup. Fourth, if commercially insured, enroll in the Eisai savings card before your first fill at Dayvigo.com. Fifth, if uninsured or underinsured, apply for Eisai's patient assistance program via NeedyMeds or ask the prescriber's office to assist with the application. Sixth, compare GoodRx prices at three or four Oklahoma pharmacies (chain and independent) before submitting the prescription, since prices vary by more than 20% across locations in some Oklahoma markets. Seventh, ask your pharmacist whether a 90-day supply is permitted under Oklahoma and DEA rules for your specific plan and whether it reduces per-unit cost. Eighth, if cost remains prohibitive after all the above, discuss compounded lemborexant from a licensed Oklahoma 503A pharmacy with your prescriber, understanding the limitations on bioequivalence data.